ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said an ovarian cancer study has been hit by Coronavirus (COVID-19) delays, meaning it won’t now be completed until sometime in the first half of this year.
The problem is with a key external supplier, which has been unable to deliver certain reagents.
This will have a knock-on impact on the sign-off for the company’s planned US lab, which requires the results from the ovarian cancer study, which would demonstrate the potential of ANGLE's Parsortix and HyCEAD platforms.
"The third-party supply chain issues were unexpected but are being closely managed and we look forward to reporting headline results from our ovarian cancer study once the sample analysis has been completed," ANGLE chief executive, Andrew Newland, said.
“Separately, we remain on track to achieve the first-ever FDA product clearance, the gold standard for medical devices globally, for a system to harvest cancer cells from patient blood for subsequent analysis, initially in metastatic breast cancer. Ongoing and constructive dialogue with FDA continues and a regulatory decision from FDA is awaited."
In the update, investors were also told the company made the first submissions in the accreditation process for new labs in both the US and UK.
ANGLE has developed pioneering technology that is able to perform liquid biopsies that pick up the tell-tale signs of cancer.